Search clinical trials for: AZD0292

Total 146 results

AstraZeneca

Recruiting

A Study to Assess the Safety, Tolerability, and Pharmacokinetics of a Single Ascending Dose of AZD0292 In Healthy Participants

Healthy Participants Study

United States
AstraZeneca
Parexel

Recruiting

A Study to Investigate Safety, Tolerability, and Pharmacokinetics of Oral AZD0233 Compared With Placebo in Healthy Adult Participants.

Dilated Cardiomyopathy

United States
Imperial College London
AstraZeneca; University of Oxford

Active, not recruiting

A Study to Determine Safety and Immunogenicity of the Candidate COVID-19 Vaccine AZD1222 Delivered by Aerosol in Healthy Adult Volunteers (COVAXAER01)

Covid19 | SARS-CoV-2 Infection

United Kingdom
AstraZeneca

Completed

Bioavailability of AZD0284 and IV Microtracer Study

Plaque Psoriasis Vulgaris

United Kingdom
AstraZeneca

Completed

A Multi-centre Study Comparing the Effects of AZD2927 and Placebo on the Electrical Activity in the Heart in Patients

Arrhythmia

Sweden, Norway
AstraZeneca

Completed

A Study to Assess the Safety, Tolerability and Pharmacokinetics After Single Ascending Intravenous Doses of AZD2927 in Healthy Male Volunteers

Healthy

Sweden
AstraZeneca

Completed

A Phase I, Open-Label, Single-Center Study to Assess the Absorption, Metabolism, and Excretion of [14C]-AZD3293 (AZD3293hADME)

Healthy Volunteers | Mass Balance Study

United States
Arrow Therapeutics

Completed

Clinical Pharmacology Study of AZD7295 in Healthy Subjects

Healthy

United Kingdom
AstraZeneca
Eli Lilly and Company

Terminated

A Study of Lanabecestat (LY3314814) in Early Alzheimer's Disease Dementia

Alzheimer's Disease

United States, Spain, Australia, Belgium, Korea, Republic of, United Kingdom, Germany, Poland, Canada, Japan, Romania, France, Puerto Rico, Hungary
AstraZeneca

Completed

Relative Bioavailability Study to Assess Two Solid Formulations Compared to an Oral Solution of AZD3293 in Healthy Male and Non-Fertile Female Subjects (BA)

Healthy Volunteers | Pharmacologic Action

United States
AstraZeneca
Eli Lilly and Company

Completed

A Study of Lanabecestat (LY3314814) in Healthy Participants

Healthy
Arrow Therapeutics

Completed

Pharmacokinetics of AZD7295 Capsules

Healthy

United Kingdom
AstraZeneca
Eli Lilly and Company

Terminated

An Efficacy and Safety Study of Lanabecestat (LY3314814) in Early Alzheimer's Disease (AMARANTH)

Alzheimer´s Disease

United States, Spain, Belgium, Australia, Hungary, Korea, Republic of, Canada, Germany, Japan, Romania, France, Poland, United Kingdom, Puerto Rico, Italy
AstraZeneca
RTI Health Solutions

Completed

EU Secondary Data Post-Authorisation Safety Study of AZD1222 (D8111R00006)

COVID-19, Vaccine Adverse Events of Special Interest

Netherlands, Spain, United Kingdom
AstraZeneca

Terminated

Study to Determine if AZD0284 is Effective and Safe in Treating Plaque Psoriasis (DERMIS)

Plaque Psoriasis Vulgaris

Denmark
AstraZeneca
Eli Lilly and Company

Terminated

A Study of Lanabecestat (LY3314814) in Participants With Mild Alzheimer's Disease Dementia (DAYBREAK-ALZ)

Alzheimer's Disease

United States, Spain, Korea, Republic of, Italy, Portugal, China, Taiwan, Czechia, Japan, Poland, France, Netherlands, United Kingdom, Germany, Russian Federation, Canada, Mexico, Denmark
AstraZeneca
Covance; Iqvia Pty Ltd

Withdrawn

AZD1222 Vaccine for the Prevention of COVID-19

COVID-19

Russian Federation
Federal University of Espirito Santo
Instituto René Rachou/Fiocruz; Escola Nacional de Saúde Pública Sérgio Arouca... and other collaborators

Recruiting

EFFECTIVENESS, SAFETY AND IMMUNOGENICITY OF THE HALF DOSE OF THE VACCINE ChadOx1 nCoV-19 (AZD1222) for COVID-19

SARS-CoV-2

Brazil
AstraZeneca
Parexel

Completed

Study to Assess the Safety, Tolerability and Pharmacokinetics and Pharmacodynamics of AZD0284 in Healthy Subjects

Plaque Psoriasis Vulgaris

United Kingdom
AstraZeneca

Completed

Study to Investigate Safety, Tolerability and PK Following Single and Multiple Ascending Doses of AZD7295 in Japanese

Healthy Subjects

Japan
Chang Gung Memorial Hospital

Recruiting

Immunogenicity of COVID-19 Vaccine on Heterologous Schedule

Healthy | Covid-19 | Vaccine | Immunogenicity | Reactogenicity

Taiwan
AstraZeneca

Active, not recruiting

AZD9291 in Combination With Ascending Doses of Novel Therapeutics

Advanced Non Small Cell Lung Cancer

Canada, Poland, Taiwan, United States, Korea, Republic of, Japan, Russian Federation, Ukraine
AstraZeneca

Completed

A Single Dose Study to Assess the Safety, Effects, and Blood and Urine Drug Levels of AZD3293 in Healthy Subjects

Healthy Elderly Volunteers | Healthy Young Volunteers

United States
Albert B. Sabin Vaccine Institute
Stanford University; Aga Khan University; Oswaldo Cruz Foundation

Completed

Immunogenicity and Safety of Fractional Booster Dose of COVID-19 Vaccines Available for Use in Pakistan/Brazil: A Phase 4 Dose-optimizing Trial

COVID-19

Brazil, Pakistan
AstraZeneca

Completed

A Phase I, Open-label Study to Assess Bioavailability of a Single Oral Dose of AZD9291 vs an IV Dose of [14C]AZD9291

Oncology

United Kingdom
AstraZeneca

Active, not recruiting

AZD9291 Versus Placebo in Patients With Stage IB-IIIA Non-small Cell Lung Carcinoma, Following Complete Tumour Resection With or Without Adjuvant Chemotherapy. (ADAURA)

Stage IB-IIIA Non-small Cell Lung Carcinoma

United States, Italy, Netherlands, Belgium, Canada, Poland, Romania, Taiwan, Thailand, Vietnam, France, Brazil, Hungary, Japan, Russian Federation, Turkey, China, Korea, Republic of, Germany, Hong Kong, Spain, Australia, Israel, Ukraine, Swed...
Federal University of Espirito Santo
Instituto René Rachou/Fiocruz

Recruiting

COVID-19 VACCINE SAFETY AND EFFECTIVENESS

SARS-CoV-2 Infection

Brazil
Humanity & Health Medical Group Limited

Completed

Antibody Response to COVID-19 Vaccines in Liver Disease Patients

Chronic Liver Disease

Hong Kong
AstraZeneca

Completed

A Two-part Single and Multiple Dose Study to Assess the Safety , Pharmacokinetics and Effects of AZD3293 in Healthy Japanese Young and Elderly Volunteers

Healthy Japanese Young and Elderly Male and Non-fertile Female Volunteers

Japan
AstraZeneca

Completed

A Two-part Multiple Dose Study to Assess the Safety and Effects of AZD3293 in Healthy Elderly and Alzheimer's Patients

Healthy Elderly Volunteers | Mild-to-moderate Alzheimer's Disease Patients

United States
AstraZeneca

Completed

Open-label PET Study With [11C]Osimertinib in Patients With EGFRm NSCLC and Brain Metastases (ODIN-BM)

Non-small Cell Lung Cancer

Sweden
Shabir Madhi
AstraZeneca

Completed

Effectiveness of Covid-19 Vaccination in Eswatini Against SARS-CoV-2 Associated Hospitalization and Death

COVID-19 | Pneumonia, Viral

Swaziland
AstraZeneca
Eli Lilly and Company

Completed

A Drug Interaction Study of Lanabecestat (LY3314814) and Warfarin in Healthy Participants

Healthy

United States
Arrow Therapeutics

Completed

Antiviral Activity of AZD7295 in HCV Carriers

Hepatitis C

New Zealand
AstraZeneca
Iqvia Pty Ltd

Completed

Study of AZD1222 for the Prevention of COVID-19 in Japan

COVID-19

Japan
R-Pharm
AstraZeneca; Russian Direct Investment Fund; The Gamaleya National Center of...

Completed

Study in Adults of AZD1222 and rAd26-S Administered as Heterologous Prime-Boost Regimen for the Prevention of COVID-19

COVID-19

Russian Federation
AstraZeneca

Completed

Phase I, Study in Chinese NSCLC Patients (AURAChinaPK)

Carcinoma, Non-Small-Cell Lung With EGFR Mutation Positive

China
AstraZeneca
Iqvia Pty Ltd

Completed

Phase III Double-blind, Placebo-controlled Study of AZD1222 for the Prevention of COVID-19 in Adults

COVID-19 | SARS-CoV-2

United States, Chile, Peru
AstraZeneca

Completed

Study to Determine the Effect of Food on the Blood Levels of AZD9291 Following Oral Dosing of a Tablet Formulation in Patients With Non-Small Cell Lung Cancer

Advanced Non Small Cell Lung Cancer | Advanced (Inoperable) Non Small Cell Lung Cancer

France, Korea, Republic of, United Kingdom, Spain
AstraZeneca

Completed

Study to Assess the Blood Levels and Safety of AZD9291 in Patients With Advanced Solid Tumours and Normal Liver Function or Mild or Moderate Liver Impairment

Solid Tumours

United States, Spain, Belgium, France, Korea, Republic of, United Kingdom
Medigen Vaccine Biologics Corp.

Completed

A Study to Evaluate Immunogenicity and Safety of MVC-COV1901 Vaccine Compared With AZD1222

COVID-19 Vaccine

Paraguay
Medigen Vaccine Biologics Corp.

Completed

A Study to Evaluate Immunogenicity and Safety of MVC-COV1901 Compared With AZD1222 Against COVID-19 in Adults

Covid19 Vaccine

Paraguay
Medigen Vaccine Biologics Corp.

Completed

A Study to Evaluate Immunogenicity and Safety of MVC-COV1901 Compared With AZD1222 in Adults Aged 18 Years and Above

COVID-19 Vaccine

Thailand
AstraZeneca
TigerMed

Completed

T790M Plasma Testing Methodology Comparison and Clinical Validation (ADELOS)

Lung Cancer

China
Shandong Cancer Hospital and Institute
AstraZeneca

Unknown

Open Label, Prospective Study to Investigate Efficacy and Safety of AZD9291 in BM From NSCLC Patients With EGFR T790M

Nonsmall Cell Lung Cancer | Brain Metastases | EGFR-TKI Resistant Mutation | AZD9291
B. Braun Melsungen AG

Completed

Comparison of Two Gelatine Solutions

Hypovolemia

Germany
AstraZeneca

Terminated

A Study of AZD1222, a Vaccine for the Prevention of COVID-19 in Immunocompromised Adults (VICTORIA)

COVID-19, SARS-CoV-2

Thailand, Ukraine
AstraZeneca

Completed

Phase II/III Study of AZD2816, for the Prevention of COVID-19 in Adults (AZD2816)

COVID-19 | SARS-CoV-2

United Kingdom, Brazil, South Africa, Poland
AstraZeneca

Completed

Drug-Drug Interaction Study With AZD9291 and Omeprazole in Healthy Volunteers

Healthy Volunteer

United States
Mahidol University
Clinixir Co., Ltd.; Program Management Unit-C (PMU-C), governed by Ministry...

Completed

Third Dose Vaccination With AstraZeneca or Pfizer COVID-19 Vaccine Among Adults Received Sinovac COVID-19 Vaccine

COVID-19 Infection | COVID-19 VACCINE

Thailand

Search clinical trials for: AZD0292

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Singapore

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations